|
A Systematic Review of Cost Effectiveness of Pembrolizumab Versus Standard Treatment for Metastatic Non-Small Cell Lung Cancer
|
|
| Author:
|
FITRIANA YULIASTUTI, SUSI ARI KRISTINA, DWI ENDARTI, TRI MURTI HANDAYANI
|
| Abstract:
|
Background: This study aimed to review the available literature on the cost-effectiveness of pembrolizumab
versus standard chemotherapy treatment as first-line treatment for metastatic Non-Small Cell Lung Cancer
(NSCLC) with Programmed Death Ligand-1 (PD-L1) from multiple paying perspectives.
Methods: A systematic review was conducted to identify related studies. Electronic databases used to identify
relevant studies are, ScienceDirect, Cochrane and PubMed. This study is limited to English and publications from
2015 to 2020. Study characteristics and result were recorded and compared.
Results: An electronic database search yield 35 articles while only 7 studies met the criteria for review. The most
widely used method in this research, includes modeling, sensitivity analysis as well as cost-effectiveness analysis
were carried out. All studies were evaluated directly cost and used quality-adjusted life years (QALY) and years of
life earned, at a discount rate of 3% and 4%. pembrolizumab compared with chemotherapy in a population with
PD-L1 TPS =50% ICER US $ US97,621/ QALY; Hongkong $ 110,922/QALY; USA $ US130,155; Switzerland $
100,000; France $ US96,050.38; China $ 36,493; China $ 136,228.82. The QHES tool was used to confirm the
quality of existing studies and showed that the score was 89.14.
Conclusion: This literature study suggests that pembrolizumab is a project to be a cost-effective option compared
to platinum-based Standard of Care (SoC) chemotherapy as the first-line treatment in adults with metastatic nonsmall cell lung cancer (NSCLC) programmed death ligand-1 (PD-L1).
|
| Keyword:
|
cost effectiveness, pembrolizumab, first-line treatment, metastatic NSCLC
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.02.090
|
| Download:
|
Request For Article
|
|
|